drugset / Trial / NCT03007147

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.

Timeline

Start
2017-08-08
Primary completion
2027-09-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Calaspargase Pegol Protein / enzyme biologic Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Daunorubicin Small molecule Intravenous
Subject Dexamethasone Small molecule Oral
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject Ifosfamide Small molecule Intravenous
Subject Imatinib Small molecule Oral
Subject MERCAPTOPURINE ANHYDROUS Small molecule Oral
Subject Methotrexate Small molecule Intrathecal
Subject Methylprednisolone Other / unclassified Intravenous
Subject Pegaspargase Protein / enzyme biologic Intravenous
Subject Prednisolone Other / unclassified Oral
Subject Thioguanine Small molecule Oral
Subject Vincristine Small molecule Intravenous
Background Dexrazoxane Small molecule Intravenous
Background Hydrocortisone Other / unclassified Intrathecal
Background Leucovorin Small molecule Oral
Background Levoleucovorin Unknown Oral
Background filgrastim Protein / enzyme biologic Subcutaneous